logo

Oragenics Inc. (OGEN)



Trade OGEN now with
  Date
  Headline
6/14/2022 7:35:14 AM Oragenics Announces Publication Of Positive Data For NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate
5/17/2022 7:47:28 AM Oragenics Says Positioning NT-CoV2-1 To Compete In Later Phase Of COVID-19 Pandemic
3/22/2022 9:09:12 AM Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
3/3/2022 9:34:24 AM Oragenics Reports Positive Data On Their Intranasal SARS-CoV-2 Vaccine Candidate In A Posted Preprint Manuscript
1/26/2022 7:36:34 AM Oragenics Announces Adjournment Of Annual Meeting Of Shareholders Due To Lack Of Quorum
12/20/2021 8:13:21 AM Oragenics Extends Collaboration With National Research Council Of Canada To Develop Vaccine Against Omicron Variant
12/1/2021 8:08:13 AM Oragenics Announces Positive COVID-19 Study Results Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate
10/4/2021 7:34:37 AM Oragenics Awarded $250,000 Grant From NIGMS For The Continued Research And Development Of Lantibiotics
9/15/2021 7:34:35 AM Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate
8/24/2021 7:33:13 AM Oragenics Announces Postponement Of Annual Meeting Of Shareholders Due To Lack Of Quorum
5/18/2021 9:32:40 AM Oragenics Believes Existing Cash And Cash Equivalents will Fund Operating Plan Into Q3 Of 2022
5/3/2021 7:36:33 AM Alan Joslyn Resigns As CEO, President And Director Of Oragenics To Pursue Other Opportunities
3/9/2021 7:11:27 AM Oragenics Enters Material Transfer Agreement With Biodextris For Mucosal Adjuvant For Intranasal COVID-19 Vaccine
1/14/2021 7:15:33 AM Oragenics Says Optimistic That Terra CoV-2 Vaccine Will Ultimately Prove To Have Several Advantages